文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

作者信息

Tang Jun, Yu Jia Xin, Hubbard-Lucey Vanessa M, Neftelinov Svetoslav T, Hodge Jeffrey P, Lin Yunqing

机构信息

Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

IQVIA, Durham, NC, USA.

出版信息

Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.

DOI:10.1038/nrd.2018.210
PMID:30482962
Abstract
摘要

相似文献

[1]
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.

Nat Rev Drug Discov. 2018-11-28

[2]
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.

Nat Rev Drug Discov. 2021-3

[3]
[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].

Rev Pneumol Clin. 2015-2

[4]
Anti-PD1/PDL1 induced psoriasis.

Curr Probl Cancer. 2017

[5]
New checkpoint inhibitors ride the immunotherapy tsunami.

Nat Rev Drug Discov. 2013-7

[6]
Resistance to PD1/PDL1 checkpoint inhibition.

Cancer Treat Rev. 2016-11-27

[7]
Part I: Checkpoint inhibitors in cancer therapy.

Immunotherapy. 2016-6

[8]
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Immunotherapy. 2017-6

[9]
The promise and challenges of immune agonist antibody development in cancer.

Nat Rev Drug Discov. 2018-6-15

[10]
Immune agonist antibodies face critical test.

Nat Rev Drug Discov. 2020-1

引用本文的文献

[1]
CRISPR/Cas9-mediated PD-1 attenuation enhances tumor infiltrating lymphocyte-based adoptive cellular therapy in humanized-PDX model of hepatocellular carcinoma.

Transl Oncol. 2025-10

[2]
Polysialic acid is upregulated on activated immune cells and negatively regulates anticancer immune activity.

Front Oncol. 2025-3-20

[3]
Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study.

BMJ Open. 2025-2-20

[4]
Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1.

EXCLI J. 2024-10-29

[5]
Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis.

ESC Heart Fail. 2025-4

[6]
Losartan-based nanocomposite hydrogel overcomes chemo-immunotherapy resistance by remodeling tumor mechanical microenvironment.

J Nanobiotechnology. 2024-10-30

[7]
Single-cell sequencing reveals the immune microenvironment associated with gastric cancer.

Genes Dis. 2024-1-26

[8]
PEDF-Enriched Extracellular Vesicle for Vessel Normalization to Potentiate Immune Checkpoint Blockade Therapy.

Biomater Res. 2024-10-1

[9]
Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.

Front Immunol. 2024

[10]
The basic biology of NK cells and its application in tumor immunotherapy.

Front Immunol. 2024

本文引用的文献

[1]
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med. 2017-10-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索